Showing results (1081-1090 of 1,194) with videos related to
Sort By:
Pageof 120
Pharmaceutical Statistics|October 2, 2020
Recurrent time-to-event models with ordinal outcomesVal Gebski, Karen Byth, Rebecca Asher, et al.Pharmaceutical Statistics|October 16, 2020
Assessing goodness-of-fit for evaluation of dose-proportionalityMartin J Wolfsegger, Alexander Bauer, Detlew Labes, et al.Pharmaceutical Statistics|July 30, 2021
Separation and the information theory surrogate evaluation approach: A penalised likelihood solutionHannah Ensor, Christopher J WeirPharmaceutical Statistics|July 26, 2021
Sample size calculation for recurrent event data with additive rates modelsLiang Zhu, Yimei Li, Yongqiang Tang, et al.Pharmaceutical Statistics|December 9, 2020
Novel concentration-QTc models for early clinical studies with parallel placebo controls: A simulation studyYasushi Orihashi, Yuji Kumagai, Kazuhito ShiosakaiPharmaceutical Statistics|February 19, 2020
Determination of hazard ratio for progression-free survival considering the tumor assessment schedule in sample size calculationTakanori TanasePharmaceutical Statistics|May 16, 2022
The utilities and pitfalls of stratified analysis in challenging situationsJin WangPharmaceutical Statistics|May 13, 2022
Two-stage subgroup-specific time-to-event (2S-Sub-TITE): An adaptive two-stage time-to-toxicity design for subgroup-specific dose finding in phase I oncology trialsAlana McGovern, Andrew G Chapple, Clement MaPharmaceutical Statistics|April 18, 2008
Consultants' forum: should post hoc sample size calculations be done?Stephen J WaltersPharmaceutical Statistics|February 10, 2021
Some design considerations incorporating early futility for single-arm clinical trials with time-to-event primary endpoints using Weibull distributionMuhammad Waleed, Jianghua He, Milind A PhadnisPageof 120